Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23600062 | 0.79 | GSK3B (0.43) | CA2CA1CA12CA3CA6 | |
| SCHEMBL4078022 | 0.78 | CA2 (0.58) | CA2CA1CA12CA3CA6 | |
| SCHEMBL233980 | 0.77 | TTR (0.37) | CA2CA1CA12CA3CA6 | |
| SCHEMBL16107022 | 0.77 | CA2 (0.40) | CA2CA1CA12CA3CA6 | |
| SCHEMBL9585491 | 0.76 | CA2 (0.52) | CA2CA1CA12CA3CA6 | |
| SCHEMBL2396144 | 0.74 | CA2 (0.54) | CA2CA1CA12CA3CA6 | |
| SCHEMBL2369004 | 0.74 | CA2 (0.50) | CA2CA1CA12CA3CA6 | |
| SCHEMBL16527195 | 0.74 | CA2 (0.50) | CA2CA1CA12CA3CA6 | |
| SCHEMBL7532498 | 0.74 | CA2 (0.50) | CA2CA1CA12CA3CA6 | |
| SCHEMBL7205889 | 0.74 | CA2 (0.50) | CA2CA1CA12CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544701-B1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIV UTAH RES FOUND (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9745406-B2 | Curable composition | CEMEDINE CO., LTD. (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-2412756-B1 | CURABLE COMPOSITION | CEMEDINE CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9289510-B2 | Polymeric drug delivery conjugates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2812363-A2 | PROCESS FOR THE TREATMENT OF A POLYMER | Consiglio Nazionale Delle Ricerche (IT) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013118100-A2 | PROCESS FOR THE TREATMENT OF A POLYMER | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2013-08-15 | — | — | WO | disclosed |
| US-20130156722-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2544701-A2 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2412756-A1 | CURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120004371-A1 | CURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| WO-2011112482-A2 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156722-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | CD44, MMP7, MMP26 | CA2 2646/4885CA1 617/4885CA12 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.